Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, it has had a relatively poor prognosis, including low five-year overall survival rates. Chemotherapy backbones have long dominated the treatment of AML, but recent drug approvals suggest a shift toward targeted agents. The approval of Rigel Pharmaceuticals’ Rezlidhia, a potent inhibitor of IDH1, underlines this trend. Rezlidhia joins Tibsovo (ivosidenib) in treating the IDH1-mutated relapsed/refractory AML population. In addition, the early- and late-phase AML pipelines are active and span several drug classes, including kinase inhibitors, radio-immunotherapeutics, menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and CAR T-cell therapies. With the uptake of new therapies and label expansions, we expect the AML therapy market to grow substantially over the 10-year forecast period.
Questions answered:
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Geographies: United States, EU5, Japan.
Primary research: 19 country-specific interviews with thought-leading hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence cases of AML by country, clinically, and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level, and regimen-level sales and patient share of key AML therapies through 2032, segmented by brands / generics / biosimilars and drug-treatable subpopulations.
Emerging therapies: Phase 2/3: 9+ drugs; coverage of select early-phase products.